212 related articles for article (PubMed ID: 32592857)
1. Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: A Retrospective Cohort Study.
Paul S; Zahurak M; Luznik L; Ambinder RF; Fuchs EJ; Bolaños-Meade J; Wagner-Johnston N; Swinnen LJ; Schoch L; Varadhan R; Jones RJ; Gladstone DE
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1679-1688. PubMed ID: 32592857
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma.
Ghosh N; Ye X; Tsai HL; Bolaños-Meade J; Fuchs EJ; Luznik L; Swinnen LJ; Gladstone DE; Ambinder RF; Varadhan R; Shanbhag S; Brodsky RA; Borrello IM; Jones RJ; Matsui W; Huff CA
Biol Blood Marrow Transplant; 2017 Nov; 23(11):1903-1909. PubMed ID: 28711728
[TBL] [Abstract][Full Text] [Related]
3. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation.
Saberian C; Abdel-Wahab N; Abudayyeh A; Rafei H; Joseph J; Rondon G; Whited L; Gruschkus S; Fa'ak F; Daher M; Knape C; Safa H; Shoukier M; Suarez-Almazor ME; Marcotulli M; Ludford K; Gulbis AM; Konopleva M; Ohanian M; Ravandi F; Garcia-Manero G; Oran B; Popat UR; Mehta R; Alousi AM; Daver N; Champlin R; Diab A; Al-Atrash G
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637601
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide for Peripheral T Cell Lymphoma: The Importance of Graft Source.
Sterling CH; Hughes MS; Tsai HL; Yarkony K; Fuchs EJ; Swinnen LJ; Paul S; Bolaños-Meade J; Luznik L; Imus PH; Ali SA; Jain T; Ambinder A; DeZern A; Huff CA; Gocke CB; Varadhan R; Wagner-Johnston N; Jones RJ; Ambinder RF
Transplant Cell Ther; 2023 Apr; 29(4):267.e1-267.e5. PubMed ID: 36549386
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age ≥55 Years.
Webster JA; Reed M; Tsai HL; Ambinder A; Jain T; Dezern AE; Levis MJ; Showel MM; Prince GT; Hourigan CS; Gladstone DE; Bolanos-Meade J; Gondek LP; Ghiaur G; Dalton WB; Paul S; Fuchs EJ; Gocke CB; Ali SA; Huff CA; Borrello IM; Swinnen L; Wagner-Johnston N; Ambinder RF; Luznik L; Gojo I; Smith BD; Varadhan R; Jones RJ; Imus PH
Transplant Cell Ther; 2023 Mar; 29(3):182.e1-182.e8. PubMed ID: 36587740
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide.
Schoch LK; Cooke KR; Wagner-Johnston ND; Gojo I; Swinnen LJ; Imus P; Fuchs EJ; Levis M; Ambinder RF; Jones RJ; Gladstone DE
Blood Adv; 2018 Sep; 2(17):2226-2229. PubMed ID: 30190282
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma.
Merryman RW; Castagna L; Giordano L; Ho VT; Corradini P; Guidetti A; Casadei B; Bond DA; Jaglowski S; Spinner MA; Arai S; Lowsky R; Shah GL; Perales MA; De Colella JMS; Blaise D; Herrera AF; Shouse G; Spilleboudt C; Ansell SM; Nieto Y; Badar T; Hamadani M; Feldman TA; Dahncke L; Singh AK; McGuirk JP; Nishihori T; Chavez J; Serritella AV; Kline J; Mohty M; Dulery R; Stamatoulas A; Houot R; Manson G; Moles-Moreau MP; Orvain C; Bouabdallah K; Modi D; Ramchandren R; Lekakis L; Beitinjaneh A; Frigault MJ; Chen YB; Lynch RC; Smith SD; Rao U; Byrne M; Romancik JT; Cohen JB; Nathan S; Phillips T; Joyce RM; Rahimian M; Bashey A; Ballard HJ; Svoboda J; Torri V; Sollini M; De Philippis C; Magagnoli M; Santoro A; Armand P; Zinzani PL; Carlo-Stella C
Leukemia; 2021 Sep; 35(9):2672-2683. PubMed ID: 33658659
[TBL] [Abstract][Full Text] [Related]
8. Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.
Kanakry CG; Tsai HL; Bolaños-Meade J; Smith BD; Gojo I; Kanakry JA; Kasamon YL; Gladstone DE; Matsui W; Borrello I; Huff CA; Swinnen LJ; Powell JD; Pratz KW; DeZern AE; Showel MM; McDevitt MA; Brodsky RA; Levis MJ; Ambinder RF; Fuchs EJ; Rosner GL; Jones RJ; Luznik L
Blood; 2014 Dec; 124(25):3817-27. PubMed ID: 25316679
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma.
Kanakry JA; Kasamon YL; Gocke CD; Tsai HL; Davis-Sproul J; Ghosh N; Symons H; Bolaños-Meade J; Gladstone DE; Swinnen LJ; Luznik L; Fuchs EJ; Jones RJ; Ambinder RF
Biol Blood Marrow Transplant; 2013 Apr; 19(4):602-6. PubMed ID: 23370119
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study.
Ito A; Kim SW; Matsuoka KI; Kawakita T; Tanaka T; Inamoto Y; Toubai T; Fujiwara SI; Fukaya M; Kondo T; Sugita J; Nara M; Katsuoka Y; Imai Y; Nakazawa H; Kawashima I; Sakai R; Ishii A; Onizuka M; Takemura T; Terakura S; Iida H; Nakamae M; Higuchi K; Tamura S; Yoshioka S; Togitani K; Kawano N; Suzuki R; Suzumiya J; Izutsu K; Teshima T; Fukuda T
Int J Hematol; 2020 Nov; 112(5):674-689. PubMed ID: 32748216
[TBL] [Abstract][Full Text] [Related]
11. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Alanazi W; Chen S; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Al-Shaibani Z; Mattsson J; Michelis FV
Acta Haematol; 2021; 144(1):66-73. PubMed ID: 32428903
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study.
Durand CM; Capoferri AA; Redd AD; Zahurak M; Rosenbloom DIS; Cash A; Avery RK; Bolaños-Meade J; Bollard CM; Bullen CK; Flexner C; Fuchs EJ; Gallant J; Gladstone DE; Gocke CD; Jones RJ; Kasamon YL; Lai J; Levis M; Luznik L; Marr KA; McHugh HL; Mehta Steinke S; Pham P; Pohlmeyer C; Pratz K; Shoham S; Wagner-Johnston N; Xu D; Siliciano JD; Quinn TC; Siliciano RF; Ambinder RF
Lancet HIV; 2020 Sep; 7(9):e602-e610. PubMed ID: 32649866
[TBL] [Abstract][Full Text] [Related]
13. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
Solomon SR; Sanacore M; Zhang X; Brown S; Holland K; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1828-34. PubMed ID: 25064745
[TBL] [Abstract][Full Text] [Related]
14. Nonmyeloablative Conditioning Regimen before T Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Hodgkin and Non-Hodgkin Lymphomas.
Montes de Oca C; Castagna L; De Philippis C; Bramanti S; Schiano JM; Pagliardini T; Collignon A; Harbi S; Mariotti J; Granata A; Maisano V; Furst S; Legrand F; Chabannon C; Carlo-Stella C; Santoro A; Blaise D; Devillier R
Biol Blood Marrow Transplant; 2020 Dec; 26(12):2299-2305. PubMed ID: 32822845
[TBL] [Abstract][Full Text] [Related]
15. Favorable outcomes of allogeneic hematopoietic stem cell transplantation with fludarabine-bendamustine conditioning and posttransplantation cyclophosphamide in classical Hodgkin lymphoma.
Beynarovich A; Lepik K; Mikhailova N; Borzenkova E; Volkov N; Moiseev I; Zalyalov Y; Kondakova E; Kozlov A; Stelmakh L; Pirogova O; Zubarovskaya L; Kulagin A; Afanasyev B
Int J Hematol; 2022 Sep; 116(3):401-410. PubMed ID: 35511399
[TBL] [Abstract][Full Text] [Related]
16. Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post-Transplantation Cyclophosphamide Graft-versus-Host Disease Prophylaxis.
Castagna L; Mussetti A; Devillier R; Dominietto A; Marcatti M; Milone G; Maura F; de Philippis C; Bruno B; Furst S; Blaise D; Corradini P; Montefusco V
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1549-1554. PubMed ID: 28499937
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide.
Webster JA; Luznik L; Tsai HL; Imus PH; DeZern AE; Pratz KW; Levis MJ; Gojo I; Showel MM; Prince G; Bolaños-Meade J; Gondek LP; Ghiaur G; Dalton WB; Jain T; Fuchs EJ; Gladstone DE; Gocke CB; Ali SA; Huff CA; Borrello IM; Swinnen L; Wagner-Johnston N; Ambinder RF; Jones RJ; Smith BD
Blood Adv; 2020 Oct; 4(20):5078-5088. PubMed ID: 33080006
[TBL] [Abstract][Full Text] [Related]
18. Thrombotic Microangiopathy after Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.
Imus PH; Tsai HL; DeZern AE; Jerde K; Swinnen LJ; Bolaños-Meade J; Luznik L; Fuchs EJ; Wagner-Johnston N; Huff CA; Gladstone DE; Ambinder RF; Gocke CB; Ali SA; Borrello IM; Varadhan R; Brodsky R; Jones RJ
Biol Blood Marrow Transplant; 2020 Dec; 26(12):2306-2310. PubMed ID: 32961372
[TBL] [Abstract][Full Text] [Related]
19. Haploidentical Transplants with Post-Transplant Cyclophosphamide for Relapsed or Refractory Hodgkin Lymphoma: The Role of Comorbidity Index and Pretransplant Positron Emission Tomography.
Marani C; Raiola AM; Morbelli S; Dominietto A; Ferrarazzo G; Avenoso D; Giannoni L; Varaldo R; Gualandi F; Grazia D; Lamparelli T; Bregante S; Van Lint MT; Ibatici A; Bovis F; Lemoli RM; Gobbi M; Bacigalupo A; Angelucci E
Biol Blood Marrow Transplant; 2018 Dec; 24(12):2501-2508. PubMed ID: 30041010
[TBL] [Abstract][Full Text] [Related]
20. Peripheral Blood Stem Cells versus Bone Marrow for T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Hodgkin Lymphoma.
Mariotti J; Devillier R; Bramanti S; Giordano L; Sarina B; Furst S; Granata A; Maisano V; Pagliardini T; De Philippis C; Kogan M; Faucher C; Harbi S; Chabannon C; Carlo-Stella C; Bouabdallah R; Santoro A; Blaise D; Castagna L
Biol Blood Marrow Transplant; 2019 Sep; 25(9):1810-1817. PubMed ID: 31128326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
